Ani Pharmaceuticals Inc (NASDAQ:ANIP) Q3 2015 Institutional Investor Sentiment Steady

Sentiment for Ani Pharmaceuticals Inc (NASDAQ:ANIP)

Ani Pharmaceuticals Inc (NASDAQ:ANIP) institutional sentiment decreased to 1.04 in Q3 2015. Its down -0.12, from 1.16 in 2015Q2. The ratio fall, as 67 hedge funds opened new and increased stock positions, while 58 reduced and sold stakes in Ani Pharmaceuticals Inc. The hedge funds in our partner’s database reported: 13.90 million shares, up from 6.48 million shares in 2015Q2. Also, the number of hedge funds holding Ani Pharmaceuticals Inc in their top 10 stock positions decreased from 3 to 2 for a decrease of 1. Sold All: 25 Reduced: 33 Increased: 47 New Position: 20.

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical firm engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company has a market cap of $453.96 million. The Company’s focused areas of product development include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving release and combination products. It has 30.42 P/E ratio. The Firm has two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, narcotics, and potent products.

About 240,513 shares traded hands. ANI Pharmaceuticals Inc (NASDAQ:ANIP) has declined 30.15% since August 28, 2015 and is downtrending. It has underperformed by 32.98% the S&P500.

According to Zacks Investment Research, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN.”

Healthcare Value Capital Llc holds 17.75% of its portfolio in ANI Pharmaceuticals Inc for 315,000 shares. Consonance Capital Management Lp owns 1.06 million shares or 5.87% of their US portfolio. Moreover, Oberweis Asset Management Inc has 1.82% invested in the company for 158,235 shares. The Connecticut-based Scholtz & Company Llc has invested 1.19% in the stock. Timpani Capital Management Llc, a Wisconsin-based fund reported 55,582 shares.#img1#

Ratings analysis reveals 100% of ANI Pharma’s analysts are positive. Out of 3 Wall Street analysts rating ANI Pharma, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $47 while the high is $51. The stock’s average target of $49.33 is 36.61% above today’s ($40.26) share price. ANIP was included in 9 notes of analysts from July 31, 2015. Standpoint Research initiated the shares of ANI Pharma in a note on November 13 with “Buy” rating. TheStreet downgraded ANI Pharma’s stock on September 2 to “Buy” rating.

Ani Pharmaceuticals Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with’s FREE daily email newsletter.

Add Comment